Full-Life Technologies Acquires Focus‑X Therapeutics

Lantheus Acquires Life Molecular Imaging (Life Molecular) for $350M Upfront

July 22, 2025

Healthcare Services

Lantheus Holdings completed its previously announced acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. The deal includes an upfront payment of $350 million and (per the earlier definitive agreement) up to $400 million in potential earn-out and milestone payments, and strengthens Lantheus’s commercial and R&D capabilities in Alzheimer’s PET diagnostics with Neuraceq (florbetaben F18).

Continuity Biosciences Acquires Focal Medical

June 4, 2025

Biotechnology

Continuity Biosciences, LLC has acquired Focal Medical, Inc., a North Carolina–based biopharmaceutical company developing iontophoresis-based, site-specific chemotherapy delivery for pancreatic cancer. The acquisition transfers Focal Medical's patent estate, device platform, equipment, licensing agreements and key personnel to Continuity as it expands its drug‑delivery and device-enabled therapeutics capabilities and advances the lead program toward clinical trials.

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

FLX Networks Acquires Focus Partners

May 10, 2023

Professional Services

FLX Networks has signed a letter of intent to acquire Focus Partners, a nationally recognized practice management and coaching firm for financial advisors. The acquisition will vertically integrate Focus Partners' practice management capabilities into FLX's technology platform to expand capabilities and scale services for wealth management firms and financial advisors.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.